S'abonner

Number of acquired melanocytic nevi in patients with melanoma and control subjects in Japan: nevus count is a significant risk factor for nonacral melanoma but not for acral melanoma - 24/08/11

Doi : 10.1016/j.jaad.2003.11.053 
Shiho Rokuhara, MD a, Toshiaki Saida, MD, PhD a, , Misae Oguchi, MD, PhD a, Kazuhiko Matsumoto, MD, PhD a, Sumio Murase, MD, PhD b, Shinji Oguchi, MD, PhD c
a Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan, 
b Department of Medical Informatics, Shinshu University School of Medicine, Matsumoto, Japan 
c Division of Dermatology, Saku Central Hospital, Usuda, Japan 

*Reprint requests: Toshiaki Saida, MD, PhD, Department of Dermatology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan.

Abstract

Background

Epidemiologic studies have suggested that number of acquired melanocytic nevi is a risk factor for melanoma development in Japanese as it is in white populations. However, there are only a few population-based studies on acquired nevi in Asian populations, and no epidemiologic study on relationship between number of acquired nevi and melanoma in Japanese populations has been reported.

Objective

The purpose of this study was to assess number, size, and distribution of acquired melanocytic nevi in a Japanese population. Particular attention was paid to evaluation of relationship between number of acquired nevi and development of nonacral or acral malignant melanoma.

Methods

In all, 82 patients with malignant melanoma and 600 control subjects were included in this study. All participants were Japanese. The number of acquired melanocytic nevi, 2 mm or larger in diameter, on the whole body except the scalp and genital areas was counted by experienced dermatologists. The participants were divided into 5 age categories (0-19, 20-39, 40-59, 60-79, and >80 years old) for the statistical analyses. This categorization adjusted the age and sex distribution between patients with melanomas and control subjects in 40- to 59-, 60- to 79-, and over 80-year-old groups.

Results

In the control Japanese population, the number of acquired melanocytic nevi on the whole body increased with age in 0- to 19-year-old age group and reached the highest number, 6.7 ± 8.1/person, in 20- to 39-year-old group. In patients with nonacral melanoma, the number of acquired nevi on the whole body in 40- to 59- and 60- to 79-year-old groups was significantly higher than that of the corresponding control group. In contrast, the rate of individuals who had acquired nevi on soles, palms, and nail apparatus was not significantly different between acral melanoma group and the control group in 40- to 59- and 60- to 79-year-old groups.

Conclusion

This study has revealed that a large number of acquired melanocytic nevi is a risk factor for the development of nonacral melanoma in Japanese and white populations. However, acquired nevi on soles, palms, and nail apparatus do not seem to be a risk factor for acral melanoma in Japanese populations.

Le texte complet de cet article est disponible en PDF.

Plan


 Supported in part by the Grant-in-Aid for Cancer Research (15-10) from the Ministry of Health, Labour and Welfare of Japan and by the Grant-in-Aid for Scientific Research (B) from the Japanese Society for the Promotion of Science, Tokyo.
Conflicts of interest: None identified.


© 2004  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 50 - N° 5

P. 695-700 - mai 2004 Retour au numéro
Article précédent Article précédent
  • Genital lentigines and melanocytic nevi with superimposed lichen sclerosus: a diagnostic challenge
  • Laila El Shabrawi-Caelen, H.Peter Soyer, Herwig Schaeppi, Lorenzo Cerroni, Carl G Schirren, Christina Rudolph, Helmut Kerl
| Article suivant Article suivant
  • Cutaneous malignant melanoma in association with mycosis fungoides
  • Alun V Evans, Julia J Scarisbrick, F.J Child, Katharine M Acland, Sean J Whittaker, Robin Russell-Jones

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.